Enteric Disease Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2025-2034

The Global Enteric Disease Testing Market was valued at USD 2.2 billion in 2024 and is estimated to grow at a CAGR of 4.2% to reach USD 3.3 billion by 2034.

The market growth is driven by the rising incidence of food- and water-borne illnesses, increased awareness of gastrointestinal diseases, and technological advancements in molecular diagnostics. Enteric diseases, caused by pathogens such as bacteria, viruses, and parasites, continue to pose a significant public health challenge, particularly in developing countries where sanitation and clean water access are limited. The growing burden of diarrheal illnesses, especially among children and the elderly, has necessitated reliable and rapid diagnostic tools to ensure early detection and effective treatment.

Technological innovation in diagnostic testing is rapidly transforming the landscape of enteric disease management. Modern enteric disease testing methods, including multiplex molecular diagnostics and real-time PCR-based techniques, offer higher sensitivity, faster turnaround times, and more accurate pathogen identification compared to traditional culture-based methods. These advancements have enabled clinicians to make quicker, evidence-based treatment decisions and improve patient outcomes. The integration of point-of-care (POC) diagnostics and automated analyzers is further expanding testing accessibility in remote areas and emergency settings, where quick detection of disease outbreaks is critical. Moreover, the rise of antimicrobial resistance has intensified the demand for precise and timely identification of enteric pathogens to guide targeted therapy and minimize the misuse of antibiotics.

By pathogen type, bacterial enteric disease testing segment generated USD 1.20 billion in 2024, owing to the high prevalence of infections caused by Salmonella, Shigella, Campylobacter, and Escherichia coli. These pathogens are major contributors to hospital admissions and public health surveillance activities globally. Improved awareness, increasing food safety regulations, and the globalization of food supply chains have heightened the importance of routine bacterial screening in both clinical and food testing laboratories. As foodborne outbreaks become more common, regulatory authorities are implementing stricter testing protocols for both imported and domestically produced food, fueling market growth in this segment.

By test type, the molecular diagnostics segment was valued at USD 729.9 million in 2024 owing to their ability to detect multiple pathogens simultaneously with high accuracy and minimal sample volume. These tests are becoming the gold standard for enteric disease diagnosis due to their speed, automation capabilities, and adaptability to centralized and decentralized testing environments. The increasing use of syndromic panel testing—which screens for a broad spectrum of enteric pathogens in a single test—is further driving the adoption of molecular platforms.

In terms of end-use, the hospitals segment held the largest market share in 2024, contributing USD 998.3 million. These facilities serve as key diagnostic hubs, especially during outbreak investigations, pediatric gastroenteritis admissions, and travel-related illness cases. With the increasing burden of gastrointestinal disorders, hospitals are investing in advanced diagnostic platforms to enable fast and accurate disease detection at the point of admission.

North America Enteric Disease Testing Market generated USD 886.2 million in 2024, propelled by strong healthcare infrastructure, stringent food safety regulations, and high awareness of infectious diseases. The United States is witnessing increasing investments in diagnostic innovation and laboratory automation, spurred by public health agencies such as the CDC and FDA. Moreover, widespread insurance coverage and a well-established reimbursement system further support market adoption of advanced diagnostics.

Major companies operating in the Enteric Disease Testing Market include BioMérieux SA, Becton, Dickinson and Company (BD), Thermo Fisher Scientific, Bio-Rad Laboratories, and DiaSorin S.p.A., among others. These companies are focusing on expanding their diagnostic portfolios, enhancing multiplex testing capabilities, and improving time-to-result through automation and digital integration. Strategic collaborations with public health institutions and investments in decentralized testing kits for rural and emergency use are key growth strategies. With the increasing threat of emerging enteric pathogens and heightened emphasis on public health preparedness, the enteric disease testing market is expected to witness sustained growth and technological innovation through the next decade. Show more